XSPRAY

Xspray Pharma

Market Cap 956.7M

Xspray Pharma has a very special business model: creating generic drugs that can be launched on a semi-exclusive basis along with the branded drug. The strategy is a high risk-high reward proposition which, if successful, can be highly profitable for investors in the near-term. The basis of the strategy is that Xspray has invented tools and a scalable technology that enables them to create fully amorphous generics or improved generics that don’t infringe on secondary patents, such as other chemical forms or product patents. After the primary substance patents expire, Xspray can launch their generic alongside the branded drug and create a market duopoly. Xspray has worked on perfecting their business model since its inception in 2006, and their expertise has led them to focus solely on drugs called protein kinase inhibitors (PKIs), selective small molecule drugs that are mostly used in cancer treatment. The enabler of the business model is a technology platform called RightSize, which is based on super critical fluid extraction (SCF) and fitted with a proprietary nozzle that allows for scalable production of amorphous drugs, overcoming a significant barrier for the industry. By focusing on generics, only smaller clinical trials in healthy volunteers are needed and Xspray can run the business efficiently. Three PKIs have been identified as the initial product candidates, and two products (HyNap-Dasa and HyNap-Sora) could reach the US market by 2021, with a third (HyNap-Nilo) by 2024. Additional product candidates are being evaluated for development. Xspray’s end goal is to license or sell the products prior to market launch.

+ more
Today
Day High
71.00
69.9
Day Low
68.60
Day Open
71.00
Prev Close
69.80
VWAP
69.7
Volume
20K
Turnover
1.376M
Top Broker
AVA
VWAP
69.5
Avg Volume
19K
Avg Turnover
1.347M
Top Brokers
AVA/ENS
VWAP
68.3
Avg Volume
21K
Avg Turnover
1.420M
Top Brokers
ENS/AVA
VWAP
65.8
Avg Volume
20K
Avg Turnover
1.348M
Top Brokers
AVA/ENS
52 week summary
Price Range
26.2
Last
92.9
Beta
N/A
Market Cap
956.7M
Total Return
122.3%
Trailing P/E
-64.2
Div Yield
0.0%
Shares Outstanding
13.7M
Stock Exchange
First North Stockholm
5 day chart Go to advanced chart

Identify and measure trend strength in stocks with our Momentum tool to identify potential entry and exit signals. The tool provides a set of the most simple but powerful indicators that identify whether a stock is under sell or buy pressure.

Relative Price Strength
Change 3 Months 15.4%
Change 12 Months 114.8%
Volume Trend
Average Volume 10 vs 60 Days 5.5%
Price VS
52 Week High -24.8%
50 Day Moving Average 12.8%
200 Day moving Average 9.2%

Add article markers

Compare Xspray Pharma to

Prev Close 0 Change 0
High 0 Avg Daily Volume 0
Low 0 Avg Daily Turnover 0
Last updated: 2018-01-16 Source: Redeye
Major Owners Equity Votes
Östersjöstiftelsen 20.2%
20.2%
Vasastaden Holding AB 10.9%
10.9%
Swedbank Robur Fonder 8.3%
8.3%
Catella Fonder 6.9%
6.9%
Anders Bladh 6.4%
6.4%
Ålandsbanken (i ägares ställe) 6.3%
6.3%
Öhman Bank S.A. 5.6%
5.6%
Avanza Pension 4.4%
4.4%
Recipharm Venture Fund AB 3.8%
3.8%
Kåre Gilstring 3.5%
3.5%
Last updated: 2018-04-19 Source: Redeye/Holdings
Timeframe Transactions Net Shares
Last 12 weeks
0 Purchases
0
0 Sales
0
Last 24 weeks
0 Purchases
0
0 Sales
0
Report Date Name Position Transaction Shares Chg Est Value (SEK)

Insider trades are behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Source: Millistream
  •  
  • Profitability
  • ROE
  • ROCE
  • ROIC
  • EBITDA margin
  • EBIT margin
  • Net margin
  • Per share data (SEK)
  • EPS
  • EPS adj
  • Dividend
  • Net debt
  • Total shares
  • Valuation
  • EV (SEKm)
  • P/E
  • P/E diluted
  • P/Sales
  • EV/Sales
  • EV/EBITDA
  • EV/EBIT
  • P/BV
  • Capital structure
  • Equity ratio
  • Debt/equity ratio
  • Net debt(SEKm)
  • Capital employed(SEKm)
  • Capital turnover rate
  • (SEKm)
  • Net sales
  • Total operating costs
  • EBITDA
  • Depreciation
  • Amortization
  • Impairment charges
  • EBIT
  • Share in profits
  • Net financial items
  • Exchange rate dif.
  • Pre-tax profit
  • Tax
  • Net earnings
  • (SEKm)
  • Assets
  • Current assets
  • Cash in banks
  • Receivables
  • Inventories
  • Other current assets
  • Current assets
  • Fixed assets
  • Tangible assets
  • Associated comp.
  • Investments
  • Goodwill
  • Cap. exp. for dev.
  • O intangible rights
  • O non-current assets
  • Total fixed assets
  • Deferred tax assets
  • Total (assets)
  • Liabilities
  • Current liabilities
  • Short-term debt
  • Accounts payable
  • O current liabilities
  • Current liabilities
  • Long-term debt
  • O long-term liabilities
  • Convertibles
  • Total Liabilities
  • Deferred tax liab
  • Provisions
  • Shareholders' equity
  • Minority interest (BS)
  • Minority & equity
  • Total liab & SE
  • (SEKm)
  • Net sales
  • Total operating costs
  • Depreciations total
  • EBIT
  • Taxes on EBIT
  • NOPLAT
  • Depreciation
  • Gross cash flow
  • Change in WC
  • Gross CAPEX
  • Free cash flow
  • 2015
  •  
  • 0.0%
  • -197.2%
  • 0.0%
  • -315.4%
  • -332.1%
  • -332.2%
  •  
  • 0.00
  • 0.00
  • 0.00
  •  
  • 0.0
  •  
  • -11.9
  • 0.0
  • 0.0
  • 0.0
  • -3.3
  • 1.0
  • 1.0
  • 0.0
  •  
  • 82.0%
  • 0.0%
  • -12
  • 0
  • 0.2
  • 2015
  •  
  •  
  • 12
  • 1
  • 0
  • 0
  • 13
  •  
  • 0
  • 0
  • 0
  • 0
  • 0
  • 1
  • 0
  • 2
  • 0
  • 15
  •  
  •  
  • 0
  • 1
  • 2
  • 3
  • 0
  • 0
  • 0
  • 3
  • 0
  • 0
  • 12
  • 0
  • 12
  • 15
  • 2015
  • 4
  • -15
  • -1
  • -12
  • 0
  • -12
  • 1
  • -11
  • 1
  • -2
  • -13
  • 2015 Q1
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015 Q2
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015 Q3
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015 Q4
  • 4
  • -15
  • -11
  • -1
  • 0
  • 0
  • -12
  • 0
  • 0
  • 0
  • -12
  • 0
  • -12
  • 2016
  •  
  • -14.0%
  • -13.8%
  • -980.7%
  • -428.7%
  • -512.6%
  • -517.4%
  •  
  • -0.64
  • -0.64
  • 0.00
  •  
  • 6.4
  •  
  • -28.8
  • 0.0
  • 0.0
  • 0.0
  • -36.4
  • 8.5
  • 7.1
  • 0.0
  •  
  • 89.6%
  • 0.0%
  • -29
  • 18
  • 0.0
  • 2016
  •  
  •  
  • 29
  • 2
  • 0
  • 0
  • 31
  •  
  • 0
  • 0
  • 0
  • 0
  • 0
  • 20
  • 0
  • 21
  • 0
  • 52
  •  
  •  
  • 0
  • 4
  • 1
  • 5
  • 0
  • 0
  • 0
  • 5
  • 0
  • 0
  • 46
  • 0
  • 46
  • 52
  • 2016
  • 1
  • -4
  • -1
  • -4
  • 0
  • -4
  • 1
  • -3
  • 2
  • -20
  • -21
  • 2016 Q1
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2016 Q2
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2016 Q3
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2016 Q4
  • 1
  • -4
  • -3
  • -1
  • 0
  • 0
  • -4
  • 0
  • 0
  • 0
  • -4
  • 0
  • -4
  • 2017
  •  
  • -13.1%
  • -13.0%
  • -74.4%
  • -3,606.0%
  • -3,957.2%
  • -3,975.3%
  •  
  • -1.07
  • -1.07
  • 0.00
  •  
  • 12.4
  •  
  • -115.5
  • 0.0
  • 0.0
  • 0.0
  • -347.9
  • 9.6
  • 8.8
  • 0.0
  •  
  • 96.4%
  • 0.0%
  • -116
  • 40
  • 0.0
  • 2017
  •  
  •  
  • 116
  • 2
  • 0
  • 0
  • 117
  •  
  • 2
  • 0
  • 0
  • 0
  • 0
  • 42
  • 0
  • 44
  • 0
  • 161
  •  
  •  
  • 0
  • 3
  • 3
  • 6
  • 0
  • 0
  • 0
  • 6
  • 0
  • 0
  • 156
  • 0
  • 156
  • 161
  • 2017
  • 0
  • -12
  • -1
  • -13
  • 0
  • -13
  • 1
  • -12
  • 1
  • -25
  • -36
  • 2017 Q1
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2017 Q2
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2017 Q3
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2017 Q4
  • 0
  • -12
  • -12
  • -1
  • 0
  • 0
  • -13
  • 0
  • 0
  • 0
  • -13
  • 0
  • -13
  • 2018 E
  • 2018 E
  • 2018 E
  • 2018 E
  • 2019 E
  • 2019 E
  • 2019 E
  • 2019 E
  • 2020 E
  • 2020 E
  • 2020 E
  • 2020 E

Estimated Values are behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Last updated: 2018-03-20 Source: Redeye
Source: Redeye

Presentations, research interviews and videos from our events listed here.

Source: Redeye